- Home
- / Vertex Pharmaceuticals
Vertex Pharmaceuticals
Stock Price
$352
2023-09-18
Market Capitalization
$90.8 B
2023-09-18
Revenue
$8.9 B
FY, 2022
Vertex Pharmaceuticals Summary
Company Summary
- Overview
- Vertex Pharmaceuticals is a biotechnology company that invests in scientific innovation to create medicines for people with cystic fibrosis. It markets TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its pipeline includes a pipeline for Alpha-1 antitrypsin deficiency; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency; and VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and other serious kidney diseases.
- Type
- Public
- Status
- Active
- Founded
- 1989
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.vrtx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer
Carmen Bozic, Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer
Operating MetricsView all
Products
6
20.0%
FY, 2020
LocationsView all
30 locations detected
Boston, MA HQ
United States
50 Northern Ave
Providence, RI
United States
225A Carolina Avenue
San Diego, CA
United States
3215 Merryfield Row
Washington, DC
United States
1050 K St NW
Watertown, MA
United States
490 Arsenal Way #110
St Leonards, NSW
Australia
level 3 suite 3/601 Pacific Hwy
Vertex Pharmaceuticals Financials
Summary Financials
- Revenue (Q2, 2023)
- $2.5B
- Gross profit (Q2, 2023)
- $2.2B
- Net income (Q2, 2023)
- $915.7M
- Cash (Q2, 2023)
- $10.2B
- EBIT (Q2, 2023)
- $1.0B
- Enterprise value
- $81.1B